Regeneron Pharmaceuticals beat Wall Street estimates for first-quarter profit and revenue, supported by strong demand for Dupixent and Libtayo. Strength in these drugs helped offset competitive pressure on Eylea, indicating resilient underlying fundamentals despite a headwind in its eye-care franchise.
Regeneron Pharmaceuticals beat Wall Street estimates for first-quarter profit and revenue, supported by strong demand for Dupixent and Libtayo. Strength in these drugs helped offset competitive pressure on Eylea, indicating resilient underlying fundamentals despite a headwind in its eye-care franchise.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
